PharmMedPolicy of the Republic of Tatarstan
Owners
History
2023: Viktor Kharitonin sold his stake in the company
Ogment Investment Limited, owned by entrepreneurs Viktor Kharitonin and Yegor Kulkov, sold a stake in PharmMedPolis RT LLC. The corresponding transaction was registered on April 24, 2023.
According to Medvestnik, Ogment Investment Limited, which, in particular, is the owner of Pharmstandard and MedInvestGroup, withdrew from the capital of Tatarstan-based PharmMedPolicy RT LLC. This organization provides business development and scaling services to medical product manufacturers. Ogment Investment Limited became a co-owner of PharmMedPolis in November 2021. Now, Medeopolis LLC (co-owners Rustem Magdeev with a 90% stake and Albert Gayfullin with 10%) and Sinext LLC (owner Denis Urmatov) are listed as the owners of this structure.
Now medical probes and personal protective equipment are being produced on the squares of the Medprompark of the Republic of Tatarstan. In particular, Medvestnik notes, in September 2022, PharmMedPolis organized the production of medical probes for the diagnosis of the Epstein-Barr herpes virus: this is one of the most common human viruses. Funds for the implementation of the project were provided by the Industrial Development Fund. The company plans to produce 600 thousand oropharyngeal probes per year, including to identify the DNA of the Epstein-Barr virus.
In addition, the production of personal protective equipment has been launched on the basis of PharmMedPolis. These are medical respirators with a FFP3 degree of protection with a valve, disposable medical masks, disposable protective overalls, non-sterile disposable gowns, doctor's protective clothing sets, disposable shoe covers, etc. It is noted that the revenue of PharmMedPolis in 2021 amounted to 144.9 million rubles, the loss - 91.6 million rubles.[1]
2022: Conclusion of contracts with Optimus and Natural Health companies on the lease of premises
On January 17, 2022, it became known that two more residents would appear on the territory of the Farmedpolis industrial park. Both Optimus and Natural Health companies lease premises on the territory of Kazan Expo for the production of their products.
 | "Lease agreements have been concluded with new residents of Prompark: Optimus LLC, leased area of 100 square meters: production of analyzers, reagents and consumables for clinical urine analysis. Natural Health JSC, leased area 1,000,0 sq. m: production of orthopedic medical products, "the message says. |  |
Production is scheduled to launch in the first quarter of 2022.
As of January, there are already four residents on the territory of the industrial park: Glovetekha and Rusatom Healthcare, as well as the production of PPE Casfor and Evotek-Mirai Genomix[2]
2021: Acquisition of 49% stake by Ogment Investments Limited
On November 9, 2021, the international company Ogment Investments Limited LLC became the owner of 49% of PharmMedPolis RT LLC, which manages Medprompark in Tatarstan. Ogment Investments Limited owns the assets of Viktor Kharitonin, including Pharmstandard, shares in Otisipharm and MedInvestGroup. Another 1% in PharmMedPolis RT was received by Kharitonin's partner Valery Egorov. Accordingly, the shares of Elbrus Magdeev and Albert Gaifullin decreased.
Before the arrival of Viktor Kharitonin, PharmMedPolis RT belonged to CEO Albert Gaifullin (10%) and Elbrus Magdeev (90%). Now they have 50% of the company through Medeopolis LLC, in which partners have a similar ratio of shares.
2019: A plant for the production of devices for genetic diagnostics will be built in Kazan
On September 4, 2019, PharmMedPolis LLC of the Republic of Tatarstan (creates a medical industrial park on the territory of the international exhibition complex Kazan Expo) and the Japanese company Mirai Genomics entered into an agreement construction Kazan with enterprises to produce Lifering devices designed for rapid genetic diagnosis of infectious diseases. It is planned to invest 2.5 billion in this project. rubles
The agreement was signed at the Eastern Economic Forum by the executive director of Mirai Genomics Tsuoshi Hirashiba and the chairman of the board of directors of PharmMedPolis RT Rustem Magdeev.
According to Albert Gayfullin, General Director of PharmMedPolis of the Republic of Tatarstan, Mirai plans to register a subsidiary in Kazan, which will become a resident of the industrial park and launch production here. The investment is expected to pay off in four years.
Lifering allows you to automatically smear the patient's nasopharynx in 10-30 minutes to determine the strain of the influenza virus that the patient is infected with, which allows you to quickly select the necessary treatment.
In the first phase of the project, an effect is expected in the form of a reduction in influenza deaths by 200 − 400 people annually, including child deaths from pneumonia.
The launch of the enterprise is scheduled for 2020. There will be produced devices of the automatic diagnostics system - analyzers and sample preparation devices, as well as consumables for them - diagnostic chips. In 2020, the company is expected to produce 1 million chips, and in five years the factory's capacity should increase to 20 million chips a year.
Devices created at the enterprise will be sold both in Russia and abroad. It is assumed that the degree of localization of production will be 90%.[3]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |